SNY On Other Exchanges
EN Paris
EN Paris
New York
text size: T | T
Back to Snapshot
Company Description

Contact Info

54, Rue La Boétie

Paris, 75008


Phone: 33 1 53 77 40 00

Fax: 33 1 53 77 42 96

g growth in sales. In the fall of 2015, it was launched in Japan with the objective of developing the market for intimate feminine-hygiene products; The above, long-standing products are supplemented by Chattem products in the U.S.. In addition to Allegra OTC and Nasacort Allergy 24H, the main products are ACT, Aspercreme, Gold Bond, Icy Hot, Cortizone-10, Selsun Blue and Unisom; The company is also improving in the Vitamins, Minerals and Supplements (VMS) market with the Omnivit range in various emerging-market countries and with the Cenovis and Nature’s Own brands on the Australian market. Generics Vaccine Products Sanofi Pasteur, the vaccines division of the company, offers a range of vaccines. In 2015, Sanofi Pasteur provided approximately 1 billion doses of vaccines, making it possible to immunize approximately 500 million people across the globe against 20 serious diseases. Sanofi Pasteur operates in the vaccine industry. In the U.S., Sanofi Pasteur is the major producer of influenza and meningitis vaccines. In Europe, Sanofi Pasteur’s vaccine products are developed and marketed by Sanofi Pasteur MSD, a joint venture that serves 19 countries. Sanofi Pasteur MSD also distributes Merck vaccines, such as Gardasil and Zostavax. Sanofi Pasteur continued to expand in Asia, Latin America, Africa, the Middle East, and Eastern Europe. In addition, Sanofi Pasteur is a key supplier to publicly funded international markets, such as UNICEF, the Pan American Health Organization (PAHO) and the Global Alliance for Vaccines and Immunization (GAVI). Pediatric, Combination and Poliomyelitis (Polio) Vaccines Sanofi Pasteur is one of the key players in pediatric vaccines in both mature and emerging markets with a portfolio of standalone and combination vaccines protecting against up to six diseases in a single injection. Pentaxim is a pediatric combination vaccine protecting against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b (Hib). As of December 31, 2015, approximately 230 million doses of Pentaxim had been distributed in approximately 100 countries, and the vaccine has been included in the national immunization programs of approximately 25 countries. Hexaxim is the only fully liquid, ready to use, 6-in-1 (hexavalent) pediatric vaccine that provides protection against diphtheria, tetanus, pertussis, polio, Hib and hepatitis B. In 2013, the EMA approved this hexavalent pediatric vaccine in the E.U., where it is sold under the brand name Hexyon in Western Europe by Sanofi Pasteur MSD and under the brand name Hexacima in Eastern Europe by Sanofi Pasteur. The roll-out of this new hexavalent vaccine began in 2013 in Germany and has ramped up with 27 countries having launched Hexaxim in their public or private immunization programs. In 2014, the WHO granted prequalification status to Hexaxim, in a one-dose vial presentation. Hexaxim is the only combination vaccine, including acellular pertussis (acP) and inactivated polio vaccines (IPV) currently prequalified by the WHO. Pentacel is a pediatric combination vaccine protecting against five diseases (diphtheria, tetanus, pertussis, polio and Hib). Pediacel is a fully liquid pentavalent vaccine protecting against diphtheria, tetanus, pertussis, polio and Hib. Act-HIB, for the prevention of Hib, is also an important growth driver within the pediatric product line. Quadracel is a combination vaccine against diphtheria, tetanus, pertussis and polio. It is used as a booster to be administered as the fifth dose in the primary series of vaccines, allowing children to complete the entire childhood schedule with as few injections as possible. Quadracel was already licensed in Canada (1997) and Australia (2002) and was licensed in the U.S. in April 2015. The U.S. commercial launch of Quadracel is planned for 2016. Shan5, developed by Shantha, is a fully-liquid 5-in-1 vaccine, protecting against five diseases (diphtheria, tetanus, pertussis, polio and Hepatitis B). Following improvements made to key manufacturing steps in the production of the antigen components of the vaccine, Shan5 regained its prequalification from the WHO in May 2014


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

SNY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNY.
View Industry Companies

Industry Analysis


Industry Average

Valuation SNY Industry Range
Price/Earnings 21.4x
Price/Sales 2.6x
Price/Book 1.6x
Price/Cash Flow 14.0x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SANOFI-ADR, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at